Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)

Breast Cancer Research and Treatment

Volumn 151, Issue 3, 2015, Pages 629-638

  Kaklamani, Virginia G ^a,e   Jeruss, Jacqueline S ^b   Hughes, Elisha ^c   Siziopikou, Kalliopi ^b   Timms, Kirsten M ^c   Gutin, Alexander ^c   Abkevich, Victor ^c   Sangale, Zaina ^c   Solimeno, Cara ^c   Brown, Krystal L ^c   Jones, Joshua ^c   Hartman, Anne Renee ^c   Meservey, Caitlin ^a   Jovanovic, Borko ^b   Helenowski, Irene ^b   Khan, Seema A ^b   Bethke, Kevin ^b   Hansen, Nora ^b   Uthe, Regina ^a   Giordano, Sara ^a   Rosen, Steven ^a   Hoskins, Kent ^d   Von Roenn, Jamie ^a   Jain, Sarika ^a   Parini, Vamsi ^b   Gradishar, William ^a   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Utah   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Biomarker studies; BRCA1; BRCA2; Breast cancer; Homologous recombination deficiency; Phase II Trials

Indexed keywords

ANDROGEN RECEPTOR; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CREATININE; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; DNA; ERIBULIN; KI 67 ANTIGEN; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN P53; SMAD3 PROTEIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FURAN DERIVATIVE; KETONE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; HYPERGLYCEMIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; CANCER GRADING; CLINICAL TRIAL; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; NEOADJUVANT THERAPY; ODDS RATIO; PATHOLOGY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; CARBOPLATIN; FEMALE; FURANS; GENES, BRCA1; GENES, BRCA2; HUMANS; KAPLAN-MEIER ESTIMATE; KETONES; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84930276139     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3435-y     Document Type: Article

References (42)

1. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52:108–118
2. Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL et al (2013) Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 108:2172–2177
3. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM et al (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33:13–21
4. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15:747–756
5. Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty P, et al. (2015) A phase II study of gemcitabine, carboplatin and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability (PrECOG 0105). J Clin Oncol. doi:10.1200/JCO.2014.57.0085
6. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA et al (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331–1337
7. Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K et al (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914–923
8. Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA et al (2014) Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 148:553–561
9. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag K, et al. (2015) TBCRC009: A multi-center Phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. doi:10.1200/JCO.2014.57.6660
10. Telli ML, Jensen KC, Abkevich V, Hartman A-R, Vinayak S, Lanchbury JS et al (2012) Homologous recombination deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)(PD09-04). Cancer Res 72(24 suppl):141s
11. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R et al (2012) Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2:366–375
12. Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T et al (2012) Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 72:5454–5462
13. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA et al (2012) Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107:1776–1782
14. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J et al (2010) A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 16:6159–6168
15. Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B et al (2014) Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 16:475
16. Nakagawa M, Bando Y, Nagao T, Morimoto M, Takai C, Ohnishi T et al (2011) Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer. Anticancer Res 31:2389–2393
17. Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH et al (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13:R22
18. Tsutsumi Y (2012) Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Jpn J Clin Oncol 42:375–386
19. Tarasewicz E, Rivas L, Hamdan R, Dokic D, Parimi V, Bernabe BP et al (2014) Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells. Cell Cycle 13:3191–3201
20. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685–700
21. Tarasewicz E, Hamdan R, Straehla J, Hardy A, Nunez LO, Zelivianski S et al (2014) CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin. Cancer Biol Ther 15:1301–1311
22. Tarasewicz E, Jeruss JS (2012) Phospho-specific Smad3 signaling: impact on breast oncogenesis. Cell Cycle 11:2443–2451
23. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2014
24. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422
25. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685
26. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q et al (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145–1153
27. Cannistra SA (2009) Phase II trials in journal of clinical oncology. J Clin Oncol 27:3073–3076
28. Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Wanders J et al (2014) A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes (S6–7). Cancer Res 72(24 suppl):109s
29. Twelves C, Akerele C, Wanders J, Cortes J (2010) Eribulin mesylate (E7389) vs treatment of physician’s choice (TPC) in patients (PTS) in patients with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Ann Oncol 21(8 suppl):viii96–viii121
30. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375–379
31. Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4:814–819
32. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171–182
33. Lambie H, Miremadi A, Pinder SE, Bell JA, Wencyk P, Paish EC et al (2003) Prognostic significance of BRCA1 expression in sporadic breast carcinomas. J Pathol 200:207–213
34. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D et al (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26:2126–2132
35. Tarasewicz E, Jeruss JS (2012) Phospho-specific Smad3 signaling: impact on breast oncogenesis. Cell Cycle 11:2443–2451
36. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566–1575
37. Velasco-Velazquez MA, Li Z, Casimiro M, Loro E, Homsi N, Pestell RG (2011) Examining the role of cyclin D1 in breast cancer. Future Oncol 7:753–765
38. Blagosklonny MV (2013) Aging is not programmed: genetic pseudo-program is a shadow of developmental growth. Cell Cycle 12:3736–3742
39. Blagosklonny MV (2013) MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer. Cell Cycle 12:1842–1847
40. Matsuura I, Chiang KN, Lai CY, He D, Wang G, Ramkumar R et al (2010) Pin1 promotes transforming growth factor-beta-induced migration and invasion. J Biol Chem 285:1754–1764
41. Nakano A, Koinuma D, Miyazawa K, Uchida T, Saitoh M, Kawabata M et al (2009) Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J Biol Chem 284:6109–6115
42. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK (2003) Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res 63:3783–3790